Eldepryl (selegiline) prevents the breakdown of a chemical in your brain referred to as Intropin. Low levels of Intropinar related to Parkinson’s disease.
Eldepryl capsules ar used at the side of dopa and carbidopa to treat symptoms of Parkinson’s disease.
Eldepryl can also be used for functions ex-directory during this medication guide.
Submit your review
Get emergency medical help if you have signs of an allergic reaction to Eldepryl: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
a light-headed feeling, like you might pass out;
confusion, hallucinations, unusual thoughts or behavior;
increased tremors or uncontrolled muscle movements;
worsening side effects of your other medications;
high levels of serotonin in the body (when taken with an antidepressant) - agitation, fever, fast heart rate, overactive reflexes, nausea, vomiting, diarrhea, loss of coordination, fainting; or
dangerously high blood pressure - severe headache, blurred vision, pounding in your neck or ears, anxiety, nausea, vomiting, severe chest pain, shortness of breath, pounding heartbeats, or seizure (convulsions).
You may have increased sexual urges, unusual urges to gamble, or other intense urges while taking this medicine. Talk with your doctor if this occurs.
Common Eldepryl side effects may include:
nausea, stomach pain, constipation;
skin rash or other irritation;
sleep problems (insomnia); or
ELDEPRYL is intended for administration to Parkinsonian patients receiving levodopa/carbidopa therapy who demonstrate a deteriorating response to this treatment. The recommended regimen for the administration of ELDEPRYL is 10 mg per day administered as divided doses of 5 mg each taken at breakfast and lunch. There is no evidence that additional benefit will be obtained from the administration of higher doses. Moreover, higher doses should ordinarily be avoided because of the increased risk of side effects. After two to three days of selegiline treatment, an attempt may be made to reduce the dose of levodopa/carbidopa. A reduction of 10 to 30% was achieved with the typical participant in the domestic placebo controlled trials who was assigned to selegiline treatment. Further reductions of levodopa/carbidopa may be possible during continued selegiline therapy.